$LIVN

Bianchi Francesco sold $96K of LIVN

Bianchi Francesco sold 1,200 shares of LivaNova PLC (LIVN) at $80.19 on 2026-06-15.

Original reporting
SEC EDGAR · Bianchi Francesco
Published Jun 17, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LIVN
Bearish
medium confidence
Mentioned
$LIVN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNBearishLow
01

Why it matters

The disclosure adds a fresh, timestamped data point on insider behavior, but the transaction’s dollar size is relatively small and does not indicate a corporate event (deal, guidance, enforcement).

02

Market read

Traders may briefly factor the insider sale into sentiment, but it is unlikely to drive a sustained repricing absent additional fundamental catalysts.

03

What to watch

The article does not state total insider holdings beyond post-transaction shares, nor whether other insiders/10b5-1 plans exist; those could contextualize the sale.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for LivaNova PLC.

Company-level read

Ticker impact

$LIVNBearishMedium confidence
Context

Director Bianchi Francesco filed an open-market sale of 1,200 LivaNova shares at $80.1900 on 2026-06-15, totaling $96,228.

Expected impact

Low-to-moderate downside bias for the stock around the filing date; magnitude likely limited given small dollar value and no 10b5-1 plan.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size (~$96k) is modest and the absence of a pre-arranged 10b5-1 plan can add some sentiment sensitivity without implying a fundamental change.

Market effects

No sector-wide read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without follow-on buys, this may not reflect bearish fundamentals.

Key entities

  • LivaNova PLC

    Subject of the Form 4 insider transaction; director sold 1,200 shares.

  • Bianchi Francesco

    Director who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LIVNMed

LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.

$LIVNMedAI 8/10

A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.